Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma

Abstract excerpt

Multiple myeloma (MM) is a plasma cell malignancy defined by complex genetics and extensive patient heterogeneity. Despite a growing arsenal of approved therapies, MM remains incurable and in need of guidelines to identify effective personalized treatments. Here, we survey the ex vivo drug and immunotherapy sensitivities across 101 bone marrow samples from 70 patients with MM using multiplexed immunofluorescence,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Immunotherapy and Immune Responses
• Share to Multiple Myeloma Research and Treatments
• Share to Protein Degradation and Inhibitors